Please login to the form below

Not currently logged in
Email:
Password:

Biogen’s corporate affairs SVP joins Sanofi

Kathleen Tregoning becomes executive vice president, external affairs

Sanofi Kathleen TregoningSanofi has appointed Kathleen Tregoning as executive vice president for external affairs.

Tregoning will join the Paris, France headquartered company from 27 February, when she will take responsibility for its market access, public affairs, government affairs, corporate communications, global policy and corporate social responsibility operations.

She brings over 20 years of policy, advocacy, stakeholder outreach and external engagement experience to the role, most recently from Biogen where she was senior vice president of corporate affairs.

Prior to this, Tregoning was vice president of Biogen's public policy and government affairs, having moved to the biotech in 2006 from her healthcare policy position in the United States Senate and United States House of Representatives.

Olivier Brandicourt, chief executive at Sanofi, said: “Kathleen brings a unique set of talents and experience to Sanofi that combines a deep political and policy expertise with highly relevant corporate experience in the biopharmaceutical industry.

"Working closely with the entire executive leadership team, Kathleen will lead our efforts to drive a better understanding of the value of our innovations among external stakeholders and ensure appropriate market access for our various healthcare offerings.”

30th January 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...